Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the Australian Patent Office has granted a key patent covering the use of the company's allogeneic "off-the-shelf" stem cell technology for the treatment of osteoarthritis and other inflammatory conditions for human and animal applications.
We are pleased to report that FY15 has been a productive and positive year for Regeneus Ltd (ASX:RGS). We have achieved a number of significant research and development, clinical and business milestones that have put the company in a good position to unlock value in our regenerative medicine technology and clinical assets in FY16 and beyond.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, announced today interim trial results showing that its allogeneic "off-the-shelf" stem cell therapy, CryoShot, has positive results on early orthopaedic developmental disease in Yearling Thoroughbreds and compares favourably against the use of conventional therapies like corticosteroids.
Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, announced today that it had entered into an agreement with one of the world's top 5 animal health companies to partner the development and commercialisation of CryoShot Canine.
Rhinomed (ASX:RNO) has had a strong first quarter of the financial year with positive traction across its consumer health and clinical businesses.
Compumedics Limited (ASX:CMP) is a leading global, innovative developer and manufacturer of medical devices.
The four patients who took part in Living Cell Technologies Limited's (ASX:LCT) (OTCMKTS:LVCLY) Phase I/IIa clinical study of NTCELL(R) for Parkinson's disease have all reached the milestone of 42 weeks post-implant. All four patients remain well, and there are no safety concerns.
